Summary
The product OXY, manufactured by Driada Medical, was tested to evaluate its composition and potency. The sample, identified by batch number 654752, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis identified oxymetholone as the active ingredient, with a measured concentration of 49.64 mg per pill. This result represents an accuracy of 99.28%, with a 0.72% variance from the labeled specification of 50 mg per pill, demonstrating a high level of dosing precision.
The testing process was completed on 28 February 2022 after being commissioned and funded by Driada Medical. The sample was retested twice to ensure accuracy. While the results closely align with the label claim, readers should evaluate the findings critically, as the testing was both submitted and funded by the manufacturer. This report is published for educational and harm reduction purposes to promote informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: OXY
- Active Ingredient: Oxymetholone
- Batch Number: 654752
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #18696
- Testing Ordered: 21 February 2022
- Sample Received: 22 February 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 50 mg per pill (as stated on the label)
- Measured Concentration: 49.64 mg per pill
- Accuracy: 99.28% (0.72% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/18696_4BG6RVKKBXZ5
- Originally Published: https://thinksteroids.com/community/posts/2920247/
Evaluation of Manufacturer-Funded Testing
The testing of OXY was both submitted and funded by Driada Medical, which necessitates careful consideration of potential biases. Manufacturer-funded testing can introduce factors like selective sample submission, which may not reflect overall product consistency. However, Janoshik Analytical’s established reputation for transparent and reliable testing lends credibility to the findings. Retesting of the sample further reinforces the reliability of the results. Independent verification by third-party testing would provide additional assurance for consumers.
Conclusion
The analysis confirms that OXY is accurately dosed with a measured concentration of 49.64 mg of oxymetholone per pill, closely matching its labeled specification. These findings validate the product’s potency and align with its label claims. This report underscores the importance of transparent testing in harm reduction, aiding consumers in making informed decisions regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
